FITC Annexin V

Pricing & Availability
Regulatory Status
RUO
Other Names
Annexin A5
Ave. Rating
Submit a Review
Product Citations
publications
AnnexinV_FITC_092908.jpg
Human T leukemia cell line, Jurkat, non-treated (top) or treated (bottom) with BioLegend’s anti-human CD95 (EOS9.1) mAb (cat. 305704) for 6 hours, then stained with Annexin V-FITC and Propidium Iodide (PI) (cat. 421301)
  • AnnexinV_FITC_092908.jpg
    Human T leukemia cell line, Jurkat, non-treated (top) or treated (bottom) with BioLegend’s anti-human CD95 (EOS9.1) mAb (cat. 305704) for 6 hours, then stained with Annexin V-FITC and Propidium Iodide (PI) (cat. 421301)
  • B_AnnexinV_FITC_092908.jpg
See FITC spectral data
Cat # Size Price Quantity Avail. Save
640905 25 tests 56,00€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
640906 100 tests 132,00€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
640945 300 tests 276,00€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Annexin V (or Annexin A5) is a member of the annexin family of intracellular proteins that binds to phosphatidylserine (PS) in a calcium-dependent manner. PS is normally only found on the intracellular leaflet of the plasma membrane in healthy cells, but during early apoptosis, membrane asymmetry is lost and PS translocates to the external leaflet. Fluorochrome-labeled Annexin V can then be used to specifically target and identify apoptotic cells. Annexin V Binding Buffer (cat. no. 422201) is recommended for use with Annexin V staining.Annexin V binding alone cannot differentiate between apoptotic cells and necrotic. Therefore, we recommend using our Helix NP™ Blue (Cat. No. 425305), Helix NP™ Green (Cat.  No. 425303) or Helix NP™ NIR (Cat. No. 425301). Early apoptotic cells will exclude 7-AAD and PI, while late stage apoptotic cells and necrotic cells will stain positively, due to the passage of these dyes into the nucleus where they bind to DNA.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
All mammalian species
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).
Preparation
The purified protein was conjugated with FITC under optimal conditions.
Concentration
Lot-specific (please contact technical support for concentration and total µg amount, or use our Lookup tool if you have a lot number.)
Storage & Handling
The Annexin V solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this product is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per 100,000 - million cells in a 100 µl volume of Annexin V Binding Buffer (Cat No. 422201). It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Annexin V Staining
1. Wash cells twice with cold BioLegend cell staining buffer (Cat. No. 420201) and then resuspend cells in Annexin V Binding Buffer (Cat. No. 422201) at a concentration of 1x106 cells/mL.
2. Transfer 100 µL of cell suspension in 5 ml test tube.
3. Add 5 µL of FITC Annexin V.
4. Add 10 µL of PI solution (Cat. No. 421301) or 7-AAD (Cat. No. 420403/420404).
5. Gently vortex the cells and incubate for 15 min at RT (25°C) in the dark.
6. Add 400 µL of Annexin V Binding Buffer (Cat. No. 422201) to each tube. Analyze by flow cytometry.


For a better experience detecting apoptosis, we now recommend Apotracker™. Cell staining with Apotracker™ is Calcium independent. Thus, no special buffers are required, and the protocol can be shortened for single-step co-staining with other reagents.

Application References
  1. Koopman G, et al. 1994. Blood 84:1415.
  2. Vermes I, et al. 1995. J. Immunol. Methods 184:39.
  3. Dachary-Prigent J, et al. 1993. Blood 81:2554.
  4. Sekine C, et al. 2009. Int Immunol. PubMed
  5. Grujic M, et al. 2010. J. Immunol. 185:1730. PubMed
  6. Mulik RS, et al. 2010. Int J Pharm. 398:190. PubMed
  7. Gupta A, et al. 2011. Leuk Res. 35:1498. PubMed
  8. Speth C,et al. 2013. J Infect Dis. 207:823. PubMed
  9. Wang Q, et al. 2013. Genes Dev. 27:615. PubMed
  10. Gill K, et al. 2013. Biocheim Biophys Acta. 830:2763. PubMed
  11. Juel HB, et al. 2013. PLoS One. 8:64619. PubMed
  12. Hellmann J, et al. 2013. J. Immunol. 191:1383. PubMed
  13. Sequier S, et al. 2013. PLoS One. 8:70937. PubMed
  14. Galski H, et al. 2013. Biochem Pharmacol. 86:584. PubMed
  15. Chen YL, et al. 2013. J Exp Med. PubMed
  16. Lin WH, et al. 2014. PLoS One. 9:83160. PubMed
  17. Salge-Bartles U, 2014. Thromb res. 133:244. PubMed
  18. Zhang X, et al. 2014. Acta Biochim Biophys Sin. 46:261. PubMed
  19. Intermann J, et al. 2014. Cell Signal. 26:1567. PubMed
  20. de Vires M, 2014. Am J Physiol Lung Cell Mol Physiol. 307:240. PubMed
  21. M Parrula MC, et al. 2014. Virus Res. 189:206. PubMed
  22. Passaro C, et al. 2014. Mol Oncol. 9:78. PubMed
  23. Tsou WI, et al. 2014. J Biol Chem. 289:25750. PubMed
  24. Awojoodu AO, et al. 2014. Blood. 124:1941. PubMed
  25. Xiong R, et al. 2014. Toxicol Appl Pharmacol. 280:285. PubMed
  26. Liu J, et al. 2015. J Mol Cell Cardiol. 80:10. PubMed
Product Citations
  1. Siddhartha V, et al. 2017. Artif Cells Nanomed Biotechnol . 10.1080/21691401.2017.1313267. PubMed
  2. Beeravolu N, McKee C, Chaudhry G 2017. J App Toxicol. 10.1002/jat.3469. PubMed
  3. Zheng Q, et al. 2017. Mol Oncol. 10.1002/1878-0261.12056. PubMed
  4. Karavasili C, et al. 2017. International Journal of Pharmaceutics. 10.1016/j.ijpharm.2017.05.061. PubMed
  5. Wang M, et al. 2017. Biochemical and Biophysical Research Communications. 10.1016/j.bbrc.2017.05.097. PubMed
  6. Chiani M, et al. 2017. Artif Cells Nanomed Biotechnol. 10.1080/21691401.2017.1337029. PubMed
  7. Hafez A, et al. 2017. Oncogenesis. 10.1038/oncsis.2017.46. PubMed
  8. Ishidome T et al. 2017. EBioMedicine. 22:89-99 . PubMed
  9. Liu Y, et al. 2017. Acta Biomater. 10.1016/j.actbio.2017.08.021. PubMed
  10. Kamiyama N, et al. 2017. Antiviral Res. 10.1016/j.antiviral.2017.08.007. PubMed
  11. Thomas A, et al. 2017. PLoS One.. 10.1371/journal.pone.0183542. PubMed
  12. Espinosa-Cueto P, et al. 2017. PLoS One.. 10.1371/journal.pone.0182126. PubMed
  13. Zervou S, et al. 2017. PLoS One.. 10.1371/journal.pone.0182994. PubMed
  14. Naqvi N,et al. 2017. Sci Rep.. 10.1038/s41598-017-12753-1. PubMed
  15. Kuntz E, et al. 2017. Nat Med. 10.1038/nm.4399. PubMed
  16. Ki H, et al. 2017. Biomed Pharmacother. 10.1016/j.biopha.2017.09.118. PubMed
  17. Schuler F, et al. 2017. Nat Commun. . 10.1038/s41467-017-01850-4. PubMed
  18. Thanuthanakhun N, et al. 2017. PLoS One. . 10.1371/journal.pone.0187610. PubMed
  19. Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed
  20. Yamauchi T et al. 2018. Cancer cell. 33(3):386-400 . PubMed
  21. Greenblatt SM, et al. 2018. Cancer Cell. 33:1111. PubMed
  22. Thompson PJ et al. 2019. Cell metabolism. 29(5):1045-1060 . PubMed
  23. Ning X, et al. 2019. Mol Cell. 74:19. PubMed
  24. Ni F, et al. 2019. Cell Stem Cell. 24:608. PubMed
  25. Litzenburger UM, et al. 2017. Genome Biol. 18:15. PubMed
  26. Noguchi F, et al. 2017. Mol Cancer Ther. 1.316666667. PubMed
  27. Rauzan M, et al. 2017. PLoS One. 12:e0174107. PubMed
  28. He J, et al. 2017. FASEB J. 31:2893. PubMed
  29. Rajavel T, et al. 2017. Sci Rep. 2.665277778. PubMed
  30. Pirali T, et al. 2017. ChemMedChem. 1.570833333. PubMed
  31. Feng W, et al. 2017. Nat Commun. 0.697916667. PubMed
  32. Venter C, et al. 2017. Cell Physiol Biochem. 43:1288. PubMed
  33. Montero–Herradón S, et al. 2017. Organogenesis. 0.675. PubMed
  34. Lee HW, et al. 2018. Am J Physiol Renal Physiol. 314:F280. PubMed
  35. Lopes–Coelho F, et al. 2017. Oncotarget. 8:82803. PubMed
  36. Lim JA, et al. 2018. BMC Cancer. 0.860416667. PubMed
  37. Bouhaddou M, et al. 2018. PLoS Comput Biol. 14:e1005985. PubMed
  38. Jones PD, et al. 2018. Arterioscler Thromb Vasc Biol. 38:1711. PubMed
  39. Nunes SC, et al. 2018. Sci Rep. 6.939583333. PubMed
  40. Schleicher EM, et al. 2018. Nucleic Acids Res. 46:8908. PubMed
  41. Clements KE, et al. 2018. Nucleic Acids Res. 46:8898. PubMed
  42. Zhao CC, et al. 2018. Oncol Rep. 40:3392. PubMed
  43. Yao Z, et al. 2018. J Virol. 92:00:00. PubMed
  44. Kumar S, et al. 2018. Cancers (Basel). 0.724305556. PubMed
  45. Sharif T, et al. 2018. Autophagy. 1.101388889. PubMed
  46. Eichelmann AK, et al. 2018. Sci Rep. 8:17553. PubMed
  47. Santos LC, et al. 2019. Nat Commun. 1.328472222. PubMed
  48. Sales–Dias J, et al. 2019. PLoS One. 14:e0217002. PubMed
  49. Zheng M, et al. 2019. Proc Natl Acad Sci U S A. 116:12422. PubMed
  50. Kumar S, et al. 2019. Int J Cancer. 146:1652. PubMed
  51. Vancsik T, et al. 2019. Cancer Med. 3.313888889. PubMed
  52. Lyu X, et al. 2019. BMC Genomics. 1.235416667. PubMed
  53. Esteghamat F, et al. 2019. Nat Genet. 51:1233. PubMed
  54. Fang P, et al. 2019. Commun Biol. 0.315972222. PubMed
  55. Mendès C, et al. 2019. Sci Rep. 9:14107. PubMed
  56. Santos I, et al. 2019. Nutrients. 2.210416667. PubMed
  57. Blümel E, et al. 2019. Oncoimmunology. 8:e1641387. PubMed
  58. Young MM, et al. 2019. Cell Death Dis. 1.004861111. PubMed
  59. Di Somma S, et al. 2019. Cancers (Basel). 1.70625. PubMed
  60. Matsumoto A, et al. 2019. J Extracell Vesicles. 9:1696517. PubMed
  61. Jing Y, et al. 2019. J Allergy Clin Immunol. 144:1377. PubMed
  62. Gladow N, et al. 2020. PLoS One. 15:e0227734. PubMed
  63. Quan M, et al. 2019. Oncol Rep. 41:3051. PubMed
  64. Fortin J, et al. 2020. Cancer Cell. 37:308. PubMed
  65. Chen MS, et al. 2019. Mol Cancer Res. 17:697. PubMed
  66. Blümel E, et al. 2020. Oncoimmunology. 9:1751561. PubMed
  67. Labi V, et al. 2019. Genes Dev. 33:1673. PubMed
  68. Bowen ME, et al. 2019. Dev Cell. 50:212. PubMed
  69. Uriostegui–Arcos M, et al. 2020. Open Biol. 10:200050. PubMed
  70. Liu H, et al. 2020. Cell Death Dis. 0.767361111. PubMed
  71. Sekine C, et al. 2009. Int Immunol. 1.079861111. PubMed
  72. Grujic M, et al. 2010. J Immunol. 185:1730. PubMed
  73. Putheti P, et al. 2010. PLoS One. 5:e8706. PubMed
  74. Speth C, et al. 2013. J Infect Dis. 207:823. PubMed
  75. Wang Q, et al. 2013. Genes Dev. 27:615. PubMed
  76. Gill K, et al. 2013. Biochim Biophys Acta. 1830:2763. PubMed
  77. Juel H, et al. 2013. PLoS One. 8:64619. PubMed
  78. Gupta A, et al. 2011. Leuk Res. 35:1498. PubMed
  79. Mulik R, et al. 2010. Int J Pharm. 398:190. PubMed
  80. Hellmann J, et al. 2013. J Immunol. 191:1383. PubMed
  81. Séguier S, et al. 2013. PLoS One. 8:70937. PubMed
  82. Passaro C, et al. 2013. Endocr Relat Cancer. 20:633. PubMed
  83. Galski H, et al. 2013. Biochem Pharmacol. 86:584. PubMed
  84. Chen Y, et al. 2013. J Exp Med. 210:2515. PubMed
  85. Lin W, et al. 2014. PLoS One. 9:83160. PubMed
  86. Salge-Bartels U, et al. 2014. Thromb Res. 133:244. PubMed
  87. Zhang X, et al. 2014. Acta Biochim Biophys Sin. 46:261. PubMed
  88. Intemann J, et al. 2014. Cell Signal. 26:1567. PubMed
  89. Vries M, et al. 2014. Am J Physiol Lung Cell Mol Physiol. 307:240. PubMed
  90. Parrula M, et al. 2014. Virus Res. 189:206. PubMed
  91. Passaro C, et al. 2014. Mol Oncol. 9:78. PubMed
  92. Tsou W, et al. 2014. J Biol Chem. 289:25750. PubMed
  93. Awojoodu A, et al. 2014. Blood. 124:1941. PubMed
  94. Xiong R, et al. 2014. Toxicol Appl Pharmacol. 280:285. PubMed
  95. Liu J, et al. 2015. J Mol Cell Cardiol. 80:10. PubMed
  96. Lhuillier C, et al. 2015. J Biol Chem. 290: 16797 - 16811. PubMed
  97. CO L, et al. 2015. Nat Commun. 6: 7739. PubMed
  98. Brigger D, et al. 2015. Cell Death Dis. 6: e1861. PubMed
  99. Fujii T, et al. 2015. Proc Natl Acad Sci U S A. 112: 12800 - 12805. PubMed
  100. Xiong R, et al. 2015. Mol Pharmacol. 88: 1045 - 1054. PubMed
  101. Polak R, et al. 2015. Blood. 126: 2404 - 2414. PubMed
  102. Slone E, et al. 2015. J Leukoc Biol. 98: 791 - 804. PubMed
  103. Kumai T, et al. 2015. Sci Rep. 5:16280. PubMed
  104. Carlsson J, et al. 2015. PLoS One. 10: 0143741. PubMed
  105. Cardoso B, et al. 2015. PLoS One. 10: 0143897. PubMed
  106. Ligtenberg M, et al. 2016. J Immunol. 196: 759 - 766. PubMed
  107. Akane K, et al. 2016. Proc Natl Acad Sci U S A. 113: 2460 - 2465. PubMed
  108. Derudder E, et al. 2016. Proc Natl Acad Sci U S A. 113: 5065-5070. PubMed
  109. Gedye C, et al. 2016. Sci Rep. 6: 25220. PubMed
  110. O'Neill K, et al. 2016. Genes Dev. 30: 973-988. PubMed
  111. Kitayama J, et al. 2016. PLoS One. 11: 0154542. PubMed
  112. Zhang J, et al. 2016. Cell Death Dis. 7:e2266. PubMed
  113. Soprano M, et al. 2016. PLoS One. 11: 0155970. PubMed
  114. Wang D, et al. 2016. J Cell Sci. 129: 2261 - 2272. PubMed
  115. Langsch S, et al. 2016. Cancer Res . 76: 4160 - 4169. PubMed
  116. Jones P, et al. 2016. J Biol Chem. 291: 16318 - 16327. PubMed
  117. Pfalzgraff A, et al. 2016. Sci Rep. 6:31577. PubMed
  118. Uchtenhagen H, et al. 2016. Nat Commun. 7:12614. PubMed
  119. Chheda Z, et al. 2016. J Immunol. 197: 2016 - 2026. PubMed
  120. Becker A, et al. 2016. Sci Rep. 6: 33847. PubMed
  121. Hrdinka M, et al. 2016. PLoS One. 11: 0162863. PubMed
  122. Geiger R, et al. 2016. Cell. 167:829-842. PubMed
  123. Liu B, et al. 2016. J Biol Chem. 291: 23869 - 23881. PubMed
  124. Yoon Y, et al. 2016. Stem Cell Reports. 7:840-853. PubMed
  125. L Chang, Y Li, D Kaplan 2016. Sci Rep. 6:36862. PubMed
  126. Douguet L, et al. 2016. PLoS One. 11:e0166164. PubMed
  127. Toutounchian J, et al. 2016. Mol Pharmacol. 91(1):1-13. PubMed
  128. Coutaz M, et al. 2016. Sci Rep. 6:39117. PubMed
  129. Herold N, et al. 2017. Nat Med. 23:256-263. PubMed
  130. Faria M, et al. 2017. PLoS One. 12(2):e0172689. PubMed
  131. Clements KE, et al. 2020. Nat Commun. 4.706944444. PubMed
  132. Schleicher EM, et al. 2020. PLoS Genet. 16:e1009176. PubMed
  133. Simoni L, et al. 2020. Cell Rep. 33:108330. PubMed
  134. Huang YL, et al. 2020. Elife. 9:00. PubMed
  135. Dewdney B, et al. 2020. Sci Rep. 10:16769. PubMed
  136. Alcon C, et al. 2020. Cell Death Dis. 0.898611111. PubMed
  137. Cai Z, et al. 2020. Cell Rep. 31:107816. PubMed
  138. Kang JH, et al. 2020. Cell Death Dis. 0.803472222. PubMed
  139. Dhoonmoon A, et al. 2020. Nucleic Acids Res. 48:7252. PubMed
  140. Ramalingam P, et al. 2020. J Exp Med. 217:00:00. PubMed
  141. Kim EH, et al. 2020. Elife. 9:00. PubMed
  142. Pajarillo E, et al. 2020. J Biol Chem. 295:3040. PubMed
  143. Pahari S, et al. 2020. Autophagy. 1.375694444. PubMed
  144. Zhang Y, et al. 2021. Cell Death Dis. 0.563194444. PubMed
  145. Xie S, et al. 2021. Sci Rep. 0.660416667. PubMed
RRID
not an antibody (BioLegend Cat. No. 640905)
not an antibody (BioLegend Cat. No. 640906)
not an antibody (BioLegend Cat. No. 640945)

Antigen Details

Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience
Gene ID
308 View all products for this Gene ID
UniProt
View information about Annexin V on UniProt.org

Related FAQs

How is your Annexin made and what sequence does it cover?

It is made in E. coli, covering human aa Met1-Asp320.

How does pH and staining temperature affect Annexin V-Phosphatidylserine binding?

Annexin-Phosphatidylserine binding is lost below pH 5.2 and with prolonged incubation over a temperature of 42°C.

Why do I need to use Annexin V Binding Buffer?

Annexin V binding requires the presence of calcium in the solution.  So, we provide Annexin V Binding Buffer (cat # 422201), which is optimized for the best performance of Annexin V staining.

Can I use RPMI during Annexin V staining?

It is best to follow protocol as described on the product data sheet. Moreover, RPMI 1640 has a relatively high concentration of phosphate and low calcium ion concentration, which negatively impacts Annexin binding to its target phosphatidylserine (PS). Measurement of cell death by using Annexin V may also be significantly affected by time of incubation on ice, calcium concentration, and type of medium.

Can I freeze Annexin V conjugates?

It should not be frozen as it will lead to loss of biological activity due to dimerization.

Is Annexin V suitable for conjugation with the Maxpar® kit for CyTOF®?

Maxpar® Labeling kits require the protein to be partially reduced, so the metal chelate can be introduced through an SH group in the hinge region of the reduced antibody. Human Annexin V contains only one Cysteine which was reported to be chemically inactive. Thus, the Maxpar® labeling protocol would not work with Annexin V, unless a free –SH group can be introduced to Annexin V.  For more information regarding SH-mediated conjugation of Annexin V please consult published papers such as this one.

Go To Top Version: 5    Revision Date: 04-20-2020

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Insert Note Here
Save Close Clear
Lab Timer
Tools
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account